Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...5455565758596061626364...266267»
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi). (On Demand | Level 1, West Hall; Poster Board No. E3) -  Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_741;    
    Compared to non-Latinx patients,Latinx patients demonstrated shorter PFS; no difference was observed in OS although these data were immature. As the majority of Latinx patients received their care at DHS, our data suggest that disparities in access to care may significantly contribute to differences in clinical outcomes of mRCC patients receiving nivo/ipi.
  • ||||||||||  A pilot trial evaluating the rapid sequencing of approved therapies in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC). (On Demand | Level 1, West Hall; Poster Board No. N9) -  Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_710;    
    P1
    In COSMIC-313, the triplet combination with cabozantinib (CABO)-ipilimumab (IPI)-nivolumab (NIVO) demonstrated promising efficacy compared to IPI-NIVO in pts with intermediate/poor risk disease, but definitive overall survival (OS) benefit has yet to be shown, and is associated with higher incidence of adverse events...Subsequent therapy is dependent on response, and can be NIVO 480mg IV Q4W (CR/PR/SD), lenvatinib 18mg + everolimus 5mg PO QD (PD on both prior regimens), or re-initiation of CABO 60mg PO QD (CR/PR/SD at CABO but PD on IPI-NIVO)...The trial is currently enrolling pts. Clinical trial information: NCT05188118.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
    Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC). (On Demand | Level 1, West Hall; Poster Board No. M20) -  Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_701;    
    P2
    The hypothesis is that use of tumor clusters to assign front-line therapy to either nivolumab/cabozantinib or ipilimumab/nivolumab will lead to a 20% greater ORR compared to unselected historical controls in CheckMate 9ER (ORR: 55%) or CheckMate 214 (ORR: 40%)...This trial is funded by the Department of Defense Kidney Cancer Research Program Clinical Trial Award (W81XWH-22-1-1033) (NCT05361720). Clinical trial information: NCT05361720.
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Enrollment closed:  Ipilimumab for Head and Neck Cancer Patients (clinicaltrials.gov) -  Jan 10, 2023   
    P1,  N=18, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal:  TILs Outperform Ipilimumab in Melanoma. (Pubmed Central) -  Jan 7, 2023   
    The first phase III study of tumor-infiltrating lymphocytes in melanoma shows that the cells are more effective than ipilimumab. Compared with the CTLA4 inhibitor, tumor-infiltrating lymphocytes yielded a higher objective response rate and longer progression-free and overall survival.
  • ||||||||||  074IC - Precision Surgical and Medical Management of Localized, Locally Advanced and Advanced Kidney Cancer (S103B) -  Jan 7, 2023 - Abstract #AUA2023AUA_289;    
    The role of surgery in patients with advanced RCC with the primary kidney tumor in place will be discussed, i.e., when to recommend cytoreductive nephrectomy and when to recommend immediate systemic therapy. Recent findings in the role of adjuvant or neoadjuvant therapy in patients with locally advanced RCC will be discussed.Learning Objectives: Differentiate among the subtypes of kidney cancer, with emphasis on clinical management decisions, and outline ways in which knowledge of kidney cancer subtypes can alter surgical and management approaches.Apply advanced strategies for robotic partial nephrectomy for patients with endophytic, hilar and multiple tumors including role of warm ischemia, intraoperative ultrasound, techniques for hemostatic control, the role of off-clamp and selective hilar clamping, the use of the retroperitoneal approach and methods for renorrhaphy.Employ techniques for management of large and/or locally advanced tumors including management of renal vein or inferior vena cava invasion and the use of lymphadenectomy.Identify the role of cytoreductive nephrectomy and/or resection of metastatic foci in patients with advanced disease.Recommend new and emerging targeted therapy and immuno-oncology options for patients with locally advanced and advanced kidney cancer, and the role of adjuvant therapy.Identify what gene tests to order on tumor tissue removed at surgery to help guide further management and therapy.
  • ||||||||||  FDA event, Journal, Checkpoint inhibition:  Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. (Pubmed Central) -  Jan 5, 2023   
    There are risks of respiratory and urinary system toxicity in male patients and reproductive system toxicity in female patients treated with the ICIs studied. Future studies on the toxicity burden of ICIs should incorporate age and sex differences to better understand the relevance of ICI toxicity burden to human immune function to develop appropriate tumor immune and therapeutic intervention strategies.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Checkpoint inhibition:  Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors. (Pubmed Central) -  Jan 4, 2023   
    Our second case illustrates that cytotoxic T-lymphocyte-associated protein-4 inhibitors can rarely lead to bullous pemphigoid, in addition to programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors. Both cases emphasise the importance of skin examinations and dermatological follow-up for patients during and even after discontinuation of immunotherapy.